Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials
@article{Rothwell2011EffectOD, title={Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials}, author={Peter M. Rothwell and F. Gerald R. Fowkes and Jill J.F. Belch and Hisao Ogawa and Charles P. Warlow and Tom W Meade}, journal={The Lancet}, year={2011}, volume={377}, pages={31-41} }
1,313 Citations
Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials
- MedicineThe Lancet
- 2012
Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials
- MedicineThe Lancet
- 2012
Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials.
- MedicineThe Lancet. Oncology
- 2012
Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials
- MedicineThe Lancet
- 2018
Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial.
- MedicineThe lancet. Gastroenterology & hepatology
- 2019
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial
- MedicineThe Lancet
- 2012
Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women
- MedicineHeart
- 2014
Conurrent evaluation of the absolute effects on cancer, CVD and major gastrointestinal bleeding showed that alternate-day use of low-dose aspirin is ineffective or harmful in the majority of women in primary prevention, but selective treatment of women ≥65 years with aspirin may improve net benefit.
Daily aspirin use and cancer mortality in a large US cohort.
- MedicineJournal of the National Cancer Institute
- 2012
Results are consistent with an association between recent daily aspirin use and modestly lower cancer mortality but suggest that any reduction in cancer mortality may be smaller than that observed with long-term aspirin use in the pooled trial analysis.
Low-dose aspirin and cancer mortality: a meta-analysis of randomized trials.
- MedicineThe American journal of medicine
- 2012
References
SHOWING 1-10 OF 59 REFERENCES
Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials
- MedicineThe Lancet
- 2010
Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies
- MedicineThe Lancet
- 2007
Low-Dose Aspirin in the Primary Prevention of Cancer: The Women’s Health Study: A Randomized Controlled Trial
- MedicineJAMA
- 2005
Results from this large-scale, long-term trial suggest that alternate day use of low-dose aspirin for an average 10 years of treatment does not lower risk of total, breast, colorectal, or other site-specific cancers.
Eff ect of aspirin on long-term risk of colorectal cancer : consistent evidence from randomised and observational studies
- Medicine
- 2007
Aspirin has been shown to reduce experimentally-induced colonic malignancies in animals, and some observational studies have reported a reduced incidence of colorectal cancers in regular users of aspirin, although there is substantial heterogeneity in apparent heterogeneity between studies.
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
- MedicineLancet
- 2009
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
- MedicineThe Lancet
- 2009
Cost-Effectiveness of Aspirin Treatment in the Primary Prevention of Cardiovascular Disease Events in Subgroups Based on Age, Gender, and Varying Cardiovascular Risk
- MedicineCirculation
- 2008
Aspirin treatment for primary prevention is cost-effective for men with a 10-year cardiovascular disease risk of >10% and for women with a risk of>15%, which occurs much later in life for women than men.
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
- MedicineJAMA
- 2008
In this study of patients with type 2 diabetes, low-dose aspirin as primary prevention did not reduce the risk of cardiovascular events.
Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.
- MedicineJournal of the National Cancer Institute
- 2009
Aspirin is effective for the prevention of colorectal adenomas in individuals with a history of these lesions and no statistically significant effect modification for any of the baseline factors studied.